Citations

Clear

3042 citation(s) found for "Kumar, S".

Association Between Thyrotropin Levels and Insulin Sensitivity in Euthyroid Obese Adolescents
Javed, Asma , Balagopal, Prabhakaran , Piccinini, Francesca, Man, Chiara Dalla , Giesler, Paula D., Laugen, Jeanette M., Kumar, Seema , Vella, Adrian , Fischer, Philip R. , Cobelli, Claudio , Dalla Man, Chiara

Mayo Clinic

Thyroid® | March 17, 2015 | Volume: 25 | Issue: 5 | Pages: 478-484

10.1089/thy.2015.0005 | PMID 25777801 Get It

Background: Thyrotropin (TSH) levels display a positive association with body mass index (BMI), and the prevalence of isolated hyperthyrotropinemia is higher in obese adolescents compared to their normal weight controls. However, the metabolic significance of the higher TSH in obese adolescents is less clear. The objective of this study was to determine the relationship between TSH concentrations and insulin sensitivity, lipids, and adipokines in euthyroid, non-diabetic, obese adolescents. Methods: Thirty-six euthyroid, non-diabetic, obese adolescents between the ages of 12 and 18 years underwent a 75 g oral glucose tolerance test. Insulin sensitivity (S i ) and pancreatic β-cell function as assessed by disposition index (DI) were measured using the oral glucose minimal model approach. Cholesterol (total, low-density lipoprotein [LDL-C], and high-density lipoprotein [HDL-C]), triglycerides (TG), interleukin-6 (IL-6), total and high molecular weight (HMW) adiponectin, and retinol binding protein-4 (RBP4) were also determined. Associations between measures of thyroid function and S i , DI, lipids, and adipokines were computed using Pearson's correlation coefficient and multiple regression analysis. Results: The mean age of the subjects was 14.3±1.88 years, and the mean BMI was 32.5±4.65 kg/m 2 ; 97% were non-Hispanic white and 47% were male. The mean TSH was 2.7±1.2 mIU/L. Increasing serum TSH was correlated with decreasing S i (log S i ) in the entire cohort ( p =0.03), but this relationship persisted only in males ( p =0.02). The correlation between TSH and S i in males remained significant after adjusting for BMI ( p =0.02). There was no correlation between TSH and pancreatic β-cell function as assessed by DI ( p =0.48). TSH correlated positively with LDL-C ( p =0.04) and IL-6 ( p =0.03), but these associations vanished or weakened after adjusting for BMI (LDL-C p- value=0.44; IL-6 p- value=0.07). Conclusions: This study suggests a sex-specific association between TSH and insulin sensitivity in euthyroid, non-diabetic, obese adolescent males. Prospective studies are warranted to explore further this sexual dimorphism in the relationship between thyroid function and insulin sensitivity and to determine if obese adolescents with insulin resistance receiving thyroid supplements for hypothyroidism would benefit from targeting TSH levels in the lower half of normal range.
How should children with West syndrome be efficiently and accurately investigated? Results from the National Infantile Spasms Consortium
Shellhaas, Renée A. , Joshi, Charuta , Keator, Cynthia, Kumar, Shilpi, Mitchell, Wendy G. , Nickels, Katherine , Berg, Anne T. , Gaillard, William D. , Wusthoff, Courtney J. , Yozawitz, Elissa , Goodkin, Howard P. , Wirrell, Elaine C., Wirrell, Elaine , Shellhaas, Renée A , Gaillard, William D , Yozawitz, Elissa G , Berg, Anne T , Nickels, Katherine C , Wusthoff, Courtney J

Mayo Clinic

Epilepsia | March 16, 2015 | Volume: 56 | Issue: 4 | Pages: 617-625

10.1111/epi.12951 | PMID 25779538 Get It

Summary Objective To prospectively evaluate the etiology of new‐onset infantile spasms and evaluate the yield of genetic and metabolic investigations in those without obvious cause after initial clinical evaluation and magnetic resonance imaging ( MRI ). Methods Twenty‐one U.S. pediatric epilepsy centers prospectively enrolled infants with newly diagnosed West syndrome in a central database. Etiology and investigations performed within 3 months of diagnosis were documented. Results From June 2012 to June 2014, a total of 251 infants were enrolled (53% male). A cause was identified in 161 (64.4%) of 250 cases (genetic,14.4%; genetic‐structural, 10.0%; structural‐congenital, 10.8%; structural‐acquired, 22.4%; metabolic, 4.8%; and infectious, 2.0%). An obvious cause was found after initial clinical assessment (history and physical examination) and/or MRI in 138 of 161, whereas further genetic and metabolic studies were revealing in another 23 cases. Of 112 subjects without an obvious cause after initial evaluation and MRI , 81 (72.3%) had undergone genetic testing, which showed a causal abnormality in 23.5% and a variant of unknown significance in 14.8%. Although metabolic studies were done in the majority (serum, 79.5%; urine, 69.6%; and cerebrospinal fluid [ CSF ], 38.4%), these revealed an etiology in only five cases (4.5%). No correlation was found between type of health insurance (public vs. private) and either genetic or metabolic testing. Significance Clinical evaluation and MRI provide a specific diagnosis in 55% of children presenting with West syndrome. We propose that a cost‐effective workup for those without obvious cause after initial clinical evaluation and MRI includes an array comparative genomic hybridization ( aCGH ) followed by an epilepsy gene panel if the microarray is not definitive, serum lactate, serum amino acids, and urine organic acids.
Soluble suppression of tumorigenicity 2 (sST2), but not galactin‐3, adds to prognostication in patients with systemic AL amyloidosis independent of NT‐proBNP and troponin T
Dispenzieri, Angela , Saenger, Amy K., Kumar, Shaji , Lacy, Martha Q. , Dingli, David , Leung, Nelson , Zeldenrust, Steven R., Hayman, Suzanne R. , Kapoor, Prashant , Grogan, Martha , Hwa, Yi L. , Russell, Stephen J. , Kyle, Robert A. , Jaffe, Allan S. , Saenger, Amy, Buadi, Francis K. , Zeldenrust, Steven, Hwa, Lisa, Jaffe, Allan, Gertz, Morie A. , Go, Ronald S. , Rajkumar, S. Vincent , Jaffe, Allan S. , Leung, Nelson , Dispenzieri, Angela , Russell, Stephen J , Dingli, David

Mayo Clinic

American Journal of Hematology | March 9, 2015 | Volume: 90 | Issue: 6 | Pages: 524-528

10.1002/ajh.24001 | PMID 25753178 Get It

The use of soluble cardiac biomarkers such as N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) and troponin has revolutionized prognostication for patients with AL amyloidosis. Soluble ST2 (sST2) and galectin‐3 have also been reported to have prognostic value in other cardiac patient populations. We identified 502 patients with AL amyloidosis, who provided a research sample and consent to review their medical records between 1/1/2006‐12/31/2010 within 90 days of their diagnosis. Samples were assayed for sST2 and galectin‐3. Within this AL amyloidosis population, overall survival (OS) was 25.5 months (95% CI 18, 35.7 months). Receiver operating curve analyses were done to detect the best cut‐points for sST2 and galectin‐3 to predict both 1‐ and 5‐year OS. The respective cut points for sST2 were 30 and 29.7 ng/mL, while the median sST2 for the entire population was 31 ng/mL (IQR 19.8, 53.6). The respective cut points for galectin‐3 were 11 and 10.4 ng/mL while the median for the entire population was 16.6 ng/mL (IQR 11.5, 24.0). Although on univariate analysis, both sST2 and galectin‐3 were prognostic, upon multivariate analysis, only sST2 was independent of troponin, NT‐proBNP, serum immunoglobulin free light chain, and blood pressure. Not only did sST2 add to previously reported prognostication systems, but a novel prognostication 5‐point system including sST2 was possible. The addition of sST2 – but not galectin‐3 – to existing prognostication systems for patients with AL amyloidosis strengthens the ability to predict for death. Am. J. Hematol. 90:524–528, 2015. © 2015 Wiley Periodicals, Inc.
Psychotherapy use in bipolar disorder: Association with functioning and illness severity
Sylvia, Louisa G. , Thase, Michael E., Reilly-Harrington, Noreen A. , Salcedo, Stephanie , Brody, Benjamin D. , Kinrys, Gustavo , Kemp, David E. , Shelton, Richard C. , Kocsis, James H., Kamali, Masoud , McInnis, Melvin G. , Friedman, Edward S., Tohen, Mauricio , Bowden, Charles L., Ketter, Terence A. , Calabrese, Joseph R. , Nierenberg, Andrew A. , Rabideau, Dustin J. , Elson, Constance M., Deckersbach, Thilo , Bobo, William V. , McElroy, Susan L. , Singh, Vivek Kumar , Kamali, Masoud , McInnis, Melvin G

Mayo Clinic

Australian & New Zealand Journal of Psychiatry | February 13, 2015 | Volume: 49 | Issue: 5 | Pages: 453-461

10.1177/0004867415569803 | PMID 25680360 Get It

Objective: This study examines characteristics of individuals with bipolar disorder who sought psychotherapy versus those who did not. Methods: Bipolar CHOICE was an 11-site comparative effectiveness study of lithium versus quetiapine in symptomatic outpatients ( N = 482) with bipolar disorder. At baseline, participants’ psychotherapy use within the past 3 months, mood, functioning, and overall health were assessed. Logistic regressions were used to test whether psychotherapy users and non-users differed on various demographic and clinical variables at baseline. Mixed-effects regression was used to determine whether psychotherapy groups differed on response to treatment over the 6-month study. Kaplan-Meier plots and log-rank tests were employed to test whether there were any differences in time to recovery (CGI-BP ≤ 2 for at least 8 weeks) between the groups. Results: Thirty one percent of participants reported using psychotherapy services. Psychotherapy users reported greater medication side effect burden than non-users and were more likely to have moderate to high suicide risk and at least one anxiety disorder. Participants not utilizing medications or psychotherapy had greater mania symptom severity, were younger, and less educated than medication only users. Medication only users were more likely to be married than the other participants. Conclusions: These data suggest that a minority of individuals with bipolar disorder attend psychotherapy services, and those that do have greater illness burden.
Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias
Kourelis, Taxiarchis , Kumar, Shaji , Kapoor, Prashant , Kyle, Robert A. , Lacy, Martha Q. , Hayman, Suzanne R. , Leung, Nelson , Dingli, David , Lust, John A., Lin, Yi , Zeldenrust, Stephen R., Dispenzieri, Angela , Kourelis, Taxiarchis V, Go, Ronald S. , Buadi, Francis K. , Gertz, Morie A. , Rajkumar, S. Vincent , Leung, Nelson , Dispenzieri, Angela , Dingli, David , Lin, Yi

Mayo Clinic

American Journal of Hematology | January 29, 2015 | Volume: 89 | Issue: 11 | Pages: 1051-1054

10.1002/ajh.23827 | PMID 25111004 Get It

AL amyloidosis (AL) is rare and frequently remains undiagnosed until organ function is compromised, even among patients with known pre‐existing untreated plasma cell dyscrasias (PCD). We identified 168 patients with AL amyloidosis who had a prior untreated PCD. The earliest symptom or sign (s/s) was defined as the first symptom reported by the patient that could be attributed to organ dysfunction caused by AL. The interval from the time of development of s/s to the establishment of diagnosis of AL (Interval‐SA) was calculated. PCD diagnosis preceded recorded onset of s/s in 75% (114/152) of patients, with a median interval‐SA for this group of 10 months. PCD was diagnosed after s/s in 25% (38/152) of patients, with a median interval‐SA of 20 months. Overall survival (OS) from diagnosis of AL was not different between the two groups. AL amyloidosis patients with an identified pre‐existing PCD had less advanced cardiac disease at AL diagnosis when compared to a control group of AL patients without preidentified PCD. Long‐term OS was not significantly superior among patients with a pre‐identified PCD. In patients with “asymptomatic” PCD, symptoms and signs of AL amyloidosis should be solicited, since timely diagnosis is important in AL amyloidosis. Am. J. Hematol. 89:1051–1054, 2014. © 2014 Wiley Periodicals, Inc.
Blind men and an elephant
Kumar, Shaji

Mayo Clinic

Blood | January 29, 2015 | Volume: 125 | Issue: 5 | Pages: 745-747

10.1182/blood-2014-12-615328 | PMID 25634613 Get It

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
Palumbo, Antonio , Bringhen, Sara , Mateos, María‐Victoria , Larocca, Alessandra , Kumar, Shaji , Offidani, Massimo , Evangelista, Andrea , Zweegman, Sonja , Musto, Pellegrino , Terpos, Evangelos , Belch, Andrew , Hájek, Roman , Stewart, A. Keith, Moreau, Philippe , Durie, Brian G.M. , Dimopoulos, Meletios Α. , Miguel, Jesús F. San , Richardson, Paul G. , Sonneveld, Pieter , Facon, Thierry T.F. , McCarthy, Philip L. , Lonial, Sagar , Zweegman, Sonja , Ludwig, Heinz , Anderson, Kenneth C. , Einsele, Hermann , Landgren, Ola , Richardson, Paul Gerard Guy , Rajkumar, S. Vincent , Hajek, Roman , Dimopoulos, Meletios A , Moreau, Philippe , Terpos, Evangelos , San-Miguel, Jesus

Mayo Clinic

Blood | January 28, 2015 | Volume: 125 | Issue: 13 | Pages: 2068-2074

10.1182/blood-2014-12-615187 | PMID 25628469 Get It

Key Points Elderly patients with myeloma are heterogeneous and assessment strategies are needed to define the frailty profile. The proposed frailty score aims to better assess patients and provide them with more suitable therapies.
The Stroke Riskometer™ App: Validation of a Data Collection Tool and Stroke Risk Predictor
Parmar, Priya , Krishnamurthi, Rita , Ikram, M. Arfan , Hofman, Albert , Mirza, Saira Saeed , Varakin, Yury, Kravchenko, Michael , Пирадов, М. А. , Thrift, Amanda G. , Wang, Wenzhi , Mandal, Dipes Kumar , Barker‐Collo, Suzanne , Sahathevan, Ramesh , Saposnik, Gustavo , Sindi, Shireen , Bornstein, Natan M. , Giroud, Maurice , Béjot, Yannick , Brainin, Michael , Narayan, K M Venkat, Correia, Manuel , Kokubo, Yoshihiro , Wiebers, David O. , BinDhim, Nasser F. , Barber, P. Alan , Pandian, Jeyaraj , Hankey, Graeme J. , Mehndiratta, Man Mohan , Azhagammal, Shobhana, Ibrahim, Norlinah Mohd, Abbott, Max , Hume, Patria , Hussein, Tasleem, Bhattacharjee, Rohit, Purohit, Mitali, Feigin, Valery L. , Narayan, K.M. Venkat , Mirza, Saira Saeed , Varakin, Yu. Ya., Norrving, Bo , Davis, Stephen M. , Kivipelto, Miia , Poulton, Richie , Freire, Antônio Fernando Menezes , Mensah, George A. , Rush, Elaine Carolyn , Hankey, Graeme J , Pandian, Jeyaraj , Kravchenko, Michael , Thrift, Amanda , Ibrahim, Norlinah Mohamed

Mayo Clinic

International Journal of Stroke | December 10, 2014 | Volume: 10 | Issue: 2 | Pages: 231-244

10.1111/ijs.12411 | PMID 25491651 Get It

Background The greatest potential to reduce the burden of stroke is by primary prevention of first-ever stroke, which constitutes three quarters of all stroke. In addition to population-wide prevention strategies (the ‘mass’ approach), the ‘high risk’ approach aims to identify individuals at risk of stroke and to modify their risk factors, and risk, accordingly. Current methods of assessing and modifying stroke risk are difficult to access and implement by the general population, amongst whom most future strokes will arise. To help reduce the burden of stroke on individuals and the population a new app, the Stroke Riskometer™, has been developed. We aim to explore the validity of the app for predicting the risk of stroke compared with current best methods. Methods 752 stroke outcomes from a sample of 9501 individuals across three countries (New Zealand, Russia and the Netherlands) were utilized to investigate the performance of a novel stroke risk prediction tool algorithm (Stroke Riskometer™) compared with two established stroke risk score prediction algorithms (Framingham Stroke Risk Score [FSRS] and QStroke). We calculated the receiver operating characteristics (ROC) curves and area under the ROC curve (AUROC) with 95% confidence intervals, Harrels C-statistic and D-statistics for measure of discrimination, R2 statistics to indicate level of variability accounted for by each prediction algorithm, the Hosmer-Lemeshow statistic for calibration, and the sensitivity and specificity of each algorithm. Results The Stroke Riskometer™ performed well against the FSRS five-year AUROC for both males (FSRS = 75·0% (95% CI 72·3%–77·6%), Stroke Riskometer™ = 74·0(95% CI 71·3%–76·7%) and females [FSRS = 70·3% (95% CI 67·9%–72·8%, Stroke Riskometer™ = 71·5% (95% CI 69·0%–73·9%)], and better than QStroke [males–59·7% (95% CI 57·3%–62·0%) and comparable to females = 71·1% (95% CI 69·0%–73·1%)]. Discriminative ability of all algorithms was low (C-statistic ranging from 0·51–0·56, D-statistic ranging from 0·01–0·12). Hosmer-Lemeshow illustrated that all of the predicted risk scores were not well calibrated with the observed event data ( P < 0·006). Conclusions The Stroke Riskometer™ is comparable in performance for stroke prediction with FSRS and QStroke. All three algorithms performed equally poorly in predicting stroke events. The Stroke Riskometer™ will be continually developed and validated to address the need to improve the current stroke risk scoring systems to more accurately predict stroke, particularly by identifying robust ethnic/race ethnicity group and country specific risk factors.
miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression
Boufraqech, Myriem , Nilubol, Naris , Gara, Sudheer Kumar, Sadowski, Samira M. , Mehta, Amit, Davis, Sean , Dreiling, Jennifer L., Copland, John A. , Smallridge, Robert C., Quezado, Martha , Kebebew, Electron , Zhang, Lisa M. , He, Mei

Mayo Clinic

Cancer Research | December 9, 2014 | Volume: 75 | Issue: 2 | Pages: 367-377

10.1158/0008-5472.can-14-2304 | PMID 25488748 Get It

Abstract Anaplastic thyroid cancer (ATC) is one of the most lethal human malignancies, but its genetic drivers remain little understood. In this study, we report losses in expression of the miRNA miR30a, which is downregulated in ATC compared with differentiated thyroid cancer and normal tissue. miR30a downregulation was associated with advanced differentiated thyroid cancer and higher mortality. Mechanistically, we found miR30a decreased cellular invasion and migration, epithelial–mesenchymal transition marker levels, lysyl oxidase (LOX) expression, and metastatic capacity. LOX was identified as a direct target of miR30a that was overexpressed in ATC and associated with advanced differentiated thyroid cancer and higher mortality rate. Consistent with its role in other cancers, we found that LOX inhibited cell proliferation, cellular invasion, and migration and metastasis in vitro and in vivo. Together, our findings establish a critical functional role for miR30a downregulation in mediating LOX upregulation and thyroid cancer progression, with implications for LOX targeting as a rational therapeutic strategy in ATC. Cancer Res; 75(2); 367–77. ©2014 AACR.
Spinal dural arteriovenous fistula with intramedullary cord hemorrhage
Schmidt, Kristen A. , Huang, Josephine F. , Black, David F. , Kaufmann, Timothy J. , Lanzino, Giuseppe , Kumar, Neeraj

Mayo Clinic

Neurology Clinical Practice | December 8, 2014 | Volume: 4 | Issue: 6 | Pages: 486-489

10.1212/cpj.0000000000000062 Get It